Clinical Trial

A Master Protocol (OLMP): A Study of LY4256984 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
Study OLMP is a master protocol that will support a collection of individual sub studies that share key design components. Participants from the originator study OWAA (NCT07100119) will be assigned to the appropriate study treatment group: Sporadic Amyotrophic Lateral Sclerosis OL01 (NCT07571174). The studies aim to evaluate the safety and tolerability of different treatments in participants with Amyotrophic Lateral Sclerosis (ALS) that will last at least 96 weeks.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-25
notable Trial sites expanded: 3 -> 9 locations 2026-06-25
Trial Details
NCT Number NCT07571200
Lead Sponsor Eli Lilly and Company
Conditions Amyotrophic Lateral Sclerosis
Enrollment 32 participants
Start Date 2026-05-14
Primary Completion 2029-06 (estimated)
Study Completion 2029-06 (estimated)
Updated on ClinicalTrials.gov 2026-07-17